Challenges of achieving clinical remission in a national cohort of juvenile-onset systemic lupus erythematosus patients

Abstract

Background and objectives

The multisystem involvement and variable course of juvenile-onset systemic lupus erythematosus (JSLE) make it difficult to assess disease activity over time. International consensus definitions of inactive disease and clinical remission have been proposed. The aim of this study was to determine the proportion of patients meeting these criteria in a large national cohort of JSLE patients and the association between achieving inactive disease and clinical remission with disease activity at presentation and time to diagnosis.

Methods

Patients diagnosed with JSLE aged ≤17 years with a minimum of 12 months follow-up participating in the UK JSLE Cohort Study were assessed against these criteria at baseline, 1 year and final clinic visit.

Results

A total of 218 patients with mean follow-up duration of 4.7 years were included and analyzed at baseline visit, of which 93 and 209 were available for analysis at the 1-year and the last follow-up visits, respectively. Eighty-five percent at 1 year and 62% at final follow-up still had active disease while only 6% and 9%, respectively, achieved inactive disease according to the proposed criteria. The majority of patients continued to require immunosuppressive treatment despite their prolonged follow-up with only two patients achieving clinical remission on medication and none off medication.

A large number of patients did not meet the criteria for inactive disease due to isolated laboratory abnormalities such as reduced lymphocyte count. Isolated low lymphocyte count was the reason for not fulfilling the inactive disease criteria in 20/79 (25%) patients at 1 year and 14/130 (11%) patients at final follow-up visit. No statistically significant differences in relation to time to diagnosis and disease activity at presentation were found between patients achieving inactive disease compared to those who did not, at 1 year and final follow-up.

Conclusion

The majority of patients failed to achieve the proposed criteria for inactive disease and continued to require immunosuppressive treatment. This reflects the high burden of disease in JSLE despite immunosuppressive therapy. A significant proportion of patients had isolated laboratory abnormalities of potentially limited clinical significance, suggesting that some modifications of the proposed criteria may be required.

Keywords

Inactive disease clinical remission lupus child juvenile systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Beresford

Davidson

. Adolescent development and SLE. Best Pract Res Clin Rheumatol 2006; 20: 353–368.

Watson

Leone

Pilkington

et al.

Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2012; 64: 2356–2365.

Ambrose

Morgan

Galloway

Ionnoau

Beresford

Isenberg

. Differences in disease phenotype and severity in SLE across age groups. Lupus 2016; 25: 1542–1550.

Griffiths

Mosca

Gordon

. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005; 19: 685–708.

Mina

Klein-Gitelman

Ravelli

et al.

Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 683–693.

Hay

Bacon

Gordon

et al.

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447–458. .

Stoll

Stucki

Malik

Pyke

Isenberg

. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996; 55: 756–760.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

Ravelli

Duarte-Salazar

Buratti

et al.

Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum 2003; 49: 501–507.

10.

Chan

Chow

Tam

et al.

Can the urine dipstick test reduce the need for microscopy for assessment of systemic lupus erythematosus disease activity?. J Rheumatol 2005; 32: 828–831.

11.

Tucker

Uribe

Fernandez

et al.

Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008; 17: 314–322.

12.

Brunner

Gladman

Ibanez

Urowitz

Silverman

. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008; 58: 556–562.

13.

Tucker

Menon

Schaller

Isenberg

. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995; 34: 866–872.

14.

Barr

Zonana-Nacach

Magder

Petri

. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682–2688.

15.

Bandeira

Buratti

Bartoli

et al.

Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006; 15: 515–520.

16.

Brunner

Silverman

Bombardier

Feldman

. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436–444.

17.

Van Vollenhoven

Mosca

Bertsias

et al.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73: 958–967. .